Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

Thanks so much for joining us on this Tuesday, October 14th. I'm Julie Morgan.

Papa Johns delivers, a blood test for Alzheimer's, and a multi-billion dollar U.S. debut.

Papa Johns closed Monday up nearly 10% after a report that Apollo Global made a $64 a share

bid for the pizza chain, according to a street insider report. Pizza without the eye is still

in the green this morning, up 3% in pre-market action at $47.

The latest update comes after a Semaphore report in June that Apollo and a Katari investment fund made a bid for the pizza chain operator.

Sources told Semaphore at the time that the deal could value the company at around $2 billion.

Papa Johns told Seeking Alpha that it has a policy of not commenting on market rumors.

The U.S. FDA has approved a blood-based biomarker test developed by Roche and Eli Lilly

that can provide an initial assessment of Alzheimer's disease and cognitive decline.

The test works by measuring a protein in human plasma, which serves as an important biomarker for

Alzheimer's pathology, including the presence of amyloid plaque. The company said that the test

provides clinicians with information that can help identify patients

in early stages of cognitive decline, who are unlikely to have Alzheimer's-related amyloid pathology.

They added that it is the only blood-based test approved for initial Alzheimer's assessment for

Alzheimer's and other cases of cognitive decline in a primary setting.

Roche and Lilly noted that the test could limit the use of more invasive and costly procedures

for Alzheimer's diagnosis.

Pay Pay Pay's valuation is expected to exceed $20 billion or over $3 trillion in its planned IPO in the U.S., which could take place

as early as December of this year.

According to Raiders, citing sources familiar with the matter.

...